2026-527114-23-00RecruitingPhase 2
OV329 Evaluation in Participants with Epilepsy and PPR
Pharmacodynamic Evaluation of OV329 in Participants with Epilepsy and a Photo-Induced Generalized Epileptiform EEG-Response Phase 2 Proof-of-Concept.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Sept 2026
Brief summary (registry, in English)
To evaluate the pharmacodynamic effect of OV329 on the IPS-induced PPR in participants with epilepsy, both after single oral dosing and after repeated dosing.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (estimated)
- First submitted
- 15 Jun 2026
- Start date
- 7 Aug 2026
- Lead sponsor
- Ovid Therapeutics Inc.
- Diseases
- Epilepsy
- EU CT number
- 2026-527114-23-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 4
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 who have epilepsy and show a reproducible epileptic brain-wave response to flashing light.
- Age
- 18 to 65 years
- Sex
- Men and women
- Disease stage
- Epilepsy with a reproducible generalized photo-induced EEG response (PPR) of at least 4 points on a frequency assessment scale at Screening and Baseline, in at least one eye condition.
- Earlier treatment
- People who are taking or have taken OV329 in the last 3 months (outside this study) cannot join.
- Biomarker or test result
- A reproducible generalized PPR (brain-wave response to flashing light) of at least 4 points at Screening and Baseline.
Main reasons for not taking part
- History of non-epileptic seizures (for example metabolic or pseudo-seizures)
- Classical juvenile myoclonus epilepsy with mainly early morning myoclonic seizures
- Taking or having taken OV329 in the last 3 months, other than in this study
- Known allergy to OV329 or possibly to one of its analogues
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who are taking or have taken OV329 as concomitant therapy within the last 3 months, with the exception of this study.
Other illness
- Participants with a history of non-epileptic seizures (e.g., metabolic or pseudo-seizures).
- Participants with a diagnosis of Classical juvenile myoclonus epilepsy characterized by exclusively or predominantly early morning myoclonic seizures, as assessed by the investigator
- Participants with a known allergy to OV329 or potentially to one of its analogues.
Who the study is looking for
- Male or female participants aged 18 to 65 years at the time of consent
- Participants with a diagnosis and history of epilepsy (see exceptions in Exclusion Criteria).
- Participants with a reproducible IPS-induced generalized PPR of at least 4 points on a frequency assessment scale at Screening and Baseline in at least one eye condition.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Human Drug Research | Leiden | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.